We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
胸腺法新联合恩替卡韦治疗慢性病毒性乙型肝炎的疗效及对患者血清 HA、Ⅳ-C、LN 和免疫功能的影响.
- Authors
石磊; 朱瑞雪; 安小翠; 叶峰; 贾海娟
- Abstract
Objective: To investigate the clinical efficacy of thymalfasin combined with entecavir in the treatment of chronic viral hepatitis B and its Influence on the serum HA, IV-C, LN levels and immune function. Methods: 102 cases of patients with CVHB admitted in our hospital from June 2013 to July 2017 were selected and evenly divided into two groups on the basis of random number table. The control group (51 patients) was treated with entecavir, while the observation group(51 patients) was combined with thymalfasin and entecavir. The clinical efficacy, changes of serum HA, Ⅳ-C, LN and peripheral blood T-cell subsets levels before and after treatment, as well as the occurrence of adverse reactions were recorded and compared between the two groups. Results: After 48 weeks of treatment, the overall effective rate of observation group reached 84.3%, which was much higher than that of the control group (P<0.05). Compared with those before treatment, the serum HA, Ⅳ-C, LN levels of both groups after 48 weeks of treatment decreased remarkably (P<0.01), the levels of CD3+, CD4+and CD4+/CD8+in peripheral blood were significantly higher than those before treatment(P<0.01), and the levels of serum HA, IV-C and LN in the observation group were significantly lower than those in the control group(P<0.01). The levels of CD3+, CD4+and CD4+/CD8+in peripheral blood were significantly higher than those before treatment(P<0.01).During the treatment, the adverse reaction rates of the control group and the observation group were 7.8% and 11.8%, respectively, and the difference was not statistically significant (P>0.05). Conclusion: Compared with ETV alone, thymus combined with ETV treatment of CVHB can effectively eliminate/alleviate the symptoms and signs of patients, improve their immune function and efficacy, and high safety, which may reduce serum HA, IV-C, LN levels. related.
- Subjects
CHRONIC hepatitis B; SYMPTOMS; RANDOM numbers; HEPATIC fibrosis; CONTROL groups
- Publication
Progress in Modern Biomedicine, 2019, Vol 19, Issue 22, p4362
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2019.22.035